MedPath

FDA Aligns with Gemini Therapeutics on APOLLO Trial Design for Bitopertin in Rare Porphyria Disorders

• Gemini Therapeutics has successfully concluded a Type C meeting with the FDA, reaching agreement on the design of APOLLO confirmatory trial for bitopertin in EPP and XLP treatment.

• The planned APOLLO trial will enroll approximately 150 patients across multiple continents in a randomized, double-blind, placebo-controlled study with a 1:1 allocation ratio.

• The company aims to submit a New Drug Application for bitopertin under the Accelerated Approval Program in the second half of 2025, with trial initiation planned for mid-2025.

Gemini Therapeutics has achieved a significant milestone in its development program for bitopertin, securing alignment with the U.S. Food and Drug Administration (FDA) on the design of its post-marketing confirmatory trial, APOLLO, for treating Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP).

Trial Design and Scope

The APOLLO trial has been structured as a comprehensive global study, incorporating key elements agreed upon during the Type C meeting with the FDA. The trial will feature a robust design, including:
  • Approximately 150 patient enrollment
  • 1:1 randomization ratio
  • Double-blind, placebo-controlled methodology
  • Clearly defined co-primary endpoints
  • Specific patient inclusion criteria
  • Predetermined dosage selection parameters

Global Implementation Strategy

The company has outlined an ambitious geographical reach for the APOLLO trial, with planned study sites across multiple regions:
  • United States
  • Canada
  • Europe
  • Australia
This multi-regional approach aims to ensure diverse patient representation and broader applicability of results.

Regulatory Pathway and Timeline

Gemini Therapeutics has established a clear regulatory timeline for bitopertin's development:
  • Trial initiation targeted for mid-2025
  • New Drug Application (NDA) submission planned for second half of 2025
  • Pursuit of approval through FDA's Accelerated Approval Program
The accelerated approval pathway reflects the urgent need for effective treatments for EPP and XLP, rare genetic disorders that currently have limited therapeutic options.

Clinical Impact and Market Significance

The advancement of bitopertin through this regulatory milestone represents a potentially significant development for patients suffering from EPP and XLP. These rare genetic disorders, characterized by severe photosensitivity and acute painful photoreactions, currently lack comprehensive treatment options.
The company's strategic approach, combining rigorous trial design with an accelerated regulatory pathway, demonstrates its commitment to addressing unmet medical needs in the rare disease space. This development also positions Gemini Therapeutics as a key player in the advancement of treatments for hematologic disorders.

Corporate Strategy

Gemini Therapeutics, previously known as Disc Medicine, Inc., continues to strengthen its position in the development of novel therapeutics for hematologic disorders. The successful Type C meeting outcome reflects the company's effective engagement with regulatory authorities and its strategic focus on bringing innovative treatments to market.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Revelation Biosciences Initiates Phase 1b Trial of Gemini for Chronic Kidney Disease

Revelation Biosciences has commenced its PRIME Phase 1b clinical study of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
The multi-site, placebo-controlled study will enroll up to forty patients across five cohorts, evaluating escalating doses of intravenously administered Gemini.

Oncolytics Biotech's Pelareorep Advances in Pancreatic Cancer Trial with Regulatory Approval

The Paul-Ehrlich-Institute (PEI) in Germany has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study.
Cohort 5 is evaluating pelareorep in combination with mFOLFIRINOX with or without atezolizumab in newly diagnosed PDAC patients.

Disc Medicine Advances Hematology Pipeline with Bitopertin NDA Plans and Phase 2 Trials

Disc Medicine is preparing for an NDA submission for bitopertin in erythropoietic protoporphyria (EPP) following positive FDA feedback, potentially leading to accelerated approval.
Phase 2 trials for DISC-0974 in anemia of myelofibrosis (MF) and chronic kidney disease (CKD) are progressing, with initial data expected in the second half of 2025.

Revelation Biosciences' Gemini Receives FDA Nod for CKD Trial

Revelation Biosciences has received FDA approval for its Investigational New Drug (IND) application for Gemini, a potential preconditioning treatment for chronic kidney disease (CKD).
A Phase 1b clinical trial is set to begin in early 2025, involving up to 40 CKD patients to assess the safety and tolerability of a single dose of Gemini.

Disc Medicine's Bitopertin Poised for Potential Accelerated FDA Approval in Erythropoietic Protoporphyria

Disc Medicine's bitopertin may receive accelerated FDA approval for erythropoietic protoporphyria (EPP) treatment based on existing clinical data.
The FDA has agreed to the design of Disc's Phase III APOLLO trial, which will serve as a confirmatory study for bitopertin.

Disc Medicine Gains FDA Alignment on Bitopertin Trial Design for Erythropoietic Protoporphyria

Disc Medicine's Type C meeting with the FDA resulted in alignment on the design of the APOLLO post-marketing confirmatory trial for bitopertin in EPP.
The APOLLO trial will assess bitopertin's efficacy using co-primary endpoints focusing on sunlight tolerance and PPIX reduction over a 6-month treatment period.

Disc Medicine Announces End-of-Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine will host a conference call on November 4 to discuss feedback from the FDA regarding the end-of-Phase 2 meeting for bitopertin.
Bitopertin is an investigational, orally administered inhibitor of GlyT1, designed to modulate heme biosynthesis for hematologic diseases.

Dimerix Advances Kidney Disease Trial with Key Endpoint Validation

Dimerix's PARASOL working group analysis supports using eGFR and proteinuria as key endpoints for FDA approval of kidney disease treatments.
The ongoing ACTION3 Phase 3 trial by Dimerix is gathering data on eGFR and proteinuria, potentially accelerating market approval.

CytoDyn Advances Leronlimab Pipeline Across Oncology, Inflammation, and HIV

CytoDyn's leronlimab sees renewed progress with the FDA lifting its clinical hold in March 2024, enabling the advancement of clinical trials.
A Phase II study of leronlimab in relapsed/refractory microsatellite stable colorectal cancer is set to begin screening patients in early 2025.

Pfizer's Giroctocogene Fitelparvovec Shows Positive Phase 3 Results in Hemophilia A Gene Therapy

Pfizer's giroctocogene fitelparvovec gene therapy significantly reduced annualized bleeding rate (ABR) in adults with moderately severe to severe hemophilia A.
The AFFINE study met its primary endpoint, demonstrating superiority in total ABR compared to routine Factor VIII replacement prophylaxis.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy